As always, it is advisable to consult a healthcare professional prior to beginning any peptide therapy or supplementation regimen.
But if your concerns are more systemic (e.g., eczema, chronic wounds), an injectable may be better indicated
Beheshtirouy S, Mirzaei F, Eyvazi S, Tarhriz V
ADVERSE EFFECTS In the cagrilintide, single-agent study between 2% and 6% (26%) of participants in the cagrilintide groups discontinued treatment prematurely because of adverse events, compared with 7% (7%) of participants in the liraglutide 3.0 mg group and 3% (3%) in the pooled placebo group
Digestive diseases and sciences, 49(1), 7377 Mogosanu, et al
For example, a peptide with a lot of hydrophobic residues might associate in a phosphate buffer and form a faint opalescence